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Abstract: Recent studies have expounded on the oncologic signifi-
cance of lymph node metastasis in nonfunctioning (NF) neuroendocrine
tumors (NETs) of the pancreas and suggest regional lymph node
dissection for treating pancreatic NET. We tested this recommendation
in NF pancreatic NET-G1, as these tumors are generally small and
suitable for function-preserving minimally invasive pancreatectomy.
From January 2005 to December 2014, medical records of patients
who underwent pancreatectomy for pathologically confirmed NF NET-
G1 of the left side of the pancreas were retrospectively reviewed.
Oncologic outcomes were compared between limited pancreatectomy
and distal pancreatosplenectomy.
Thirty-five patients (14 males and 21 females) with a mean age of
55.9 11.4 years were enrolled in this study. Six patients (17.1%)
underwent distal pancreatosplenectomy. Limited pancreatectomies
comprised 15 spleen-preserving distal pancreatectomies (42.8%), 10
enucleations (28.6%), and 4 central pancreatectomies (11.4%). Lymph
node metastasis was not found in 6 patients who underwent distal
pancreatectomy with a splenectomy; meanwhile, the others were
regarded as pNx since no lymph node retrieval was attempted during
the limited pancreatectomy. Overall disease-free survival was 36.5
months (95% confidence interval [CI]: 25.9–47.1) and no tumor-related
mortality was noted. Minimally invasive pancreatectomy (P¼ 0.557)
and limited pancreatectomy (P¼ 0.758) showed no adverse impact in
treating NF NET-G1 of the left side of the pancreas.
The oncologic significance of lymph node metastasis is overesti-
mated in NF NET-G1 of the left side of the pancreas. Routine conven-
tional distal pancreatosplenectomy to retrieve regional lymph nodes
may be too excessive in treating NF NET-G1 of the distal pancreas.
(Medicine 94(36):e1404)
Abbreviations: CI = confidence interval, G = grade, NEC =
neuroendocrine carcinoma, NET = neuroendocrine tumor, NF =g Hwang, MD, Ch , MD, PhD,
Woo Jung Lee, MD, PhD
INTRODUCTION
T here is some debate as to which surgical option is appro-priate for treating a single nonfunctioning (NF) neuroendo-
crine tumor (NET) on the left side of the pancreas (as seen in
Figure 1). Pancreatic NETs, known as islet cell tumors, are low
grade malignant tumors that rarely occur, about 3% of all
primary pancreatic neoplasms.1 NETs are characterized as
G1 or G2 NETs and neuroendocrine carcinomas (NEC, highly
malignant).2 In pancreatic NET, surgery is the primary treat-
ment for localized tumors, and remains the treatment of choice
for metastatic disease.3 Thus far, surgery has proven to be the
only curative treatment thereof, providing 5-year survival rates
of 80% to 100% in resectable cases.4
Commonly, reports suggest that NF NET of the pancreas
can be removed by minimally invasive approaches (robotic or
laparoscopic) and by function-preserving limited pancreatect-
omy, such as enucleation, central pancreatectomy, and spleen-
preserving pancreatectomy.5,6 However, recent studies have
shown that lymph node metastasis from NET varies in grade
(G1, 15% to 20%; G2, 30% to 40%; G3, more than 50%)7 and
that metastasis to lymph nodes is a poor prognostic factor.8–10
Therefore, regional lymph node dissection is strongly recom-
mended in treating NET of the pancreas. Accordingly, this
would mean that distal pancreatosplenectomy for lymph node
retrieval would be appropriate in treating NF NET should it be
found in the left side of the pancreas.
The reasons why we chose to investigate NF NET-G1 of
the distal pancreas are as follows: First, greater use of more
advanced imaging modalities has led to an increased incidence
of asymptomatic NETs.11,12 Second, most NF NETs are rela-
tively small in size.7,13 Third, NF NET-G1 shows quite good
survival outcomes in long-term survival.7,14 Considering that
minimally invasive enucleation, spleen-preserving distal pan-
createctomy, and central pancreatectomy are regarded as safe
and effective treatment options to treat benign and low-grade
malignant tumors, function-preserving andminimally invasive
pancreatectomy could be ideal approaches for NF NET-G1 of
the distal pancreas. Lastly, laparoscopic distal pancreatectomy
is generally accepted as safe and effective. On the contrary,
applications of laparoscopic pancreaticoduodenectomy are
still debated, and its counterpart of limited pancreatectomy
(ie, duodenum-preserving pancreatic head resection) is tech-
nically demanding.
Therefore, in this study, we focused specifically on NF
NET-G1 of the left side of the pancreas, for which minimally
invasive and limited pancreatectomy are suitable. We evaluated
oncologic outcomes of NF NET-G1s of the left side of the
pancreas according to clinicopathological factors, surgicalof pancreatectomy to suggest the role
nd function-preserving limited pancrea-
hereof.
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Continuous variables are described as mean standard
deviation, and categorical variables are described as frequencies
(%). Student t test and chi-squared test or Fisher’s exact test
FIGURE 1. A 61-year-old male patient with NET of the left side of
the pancreas (white arrow). He underwent laparoscopic spleen-
preserving distal pancreatectomy. He was found to have no
evidence of tumor recurrence after more than 70 months of
postoperative follow-up. Pathologic diagnosis revealed a 3-cm
NET-G1 with a Ki 67 index <1% and no mitosis. NET ¼
Yoo et al Medicine  Volume 94, Number 36, September 2015METHODS
This study was approved by our institutional review board,
and informed consent was not required. From January 2005 to
December 2014, the medical records of patients who underwent
pancreatectomy for a pathological diagnosis of NET of the left
side of the pancreas were retrospectively reviewed. Only
patients fulfilling inclusion criteria were included in this study
(criteria are shown in Table 1 and Figure 2). Clinicopathological
variables, such as age, gender, symptom, radiologic tumor size,
neuroendocrine tumor.surgical procedures, grade, Ki-67 proliferative index, compli-
cations, recurrence, and disease-specific mortality, were
checked. A specialized pathologist re-evaluated tumor grades
TABLE 1. Inclusion and Exclusion Criteria
Inclusion criteria
Left-sided (neck, body, tail of the pancreas) nonfunctioning
NET (G1)
No distant metastasis
Single tumor
Patients with distal pancreato-splenectomy (DPS), spleen-
preserving DP (SpDP), enucleation, central pancreatectomy
Open, laparoscopic, or robotic approach
Exclusion criteria
MEN/multiple NETs/functioning NETs
G2, NEC (G3)
Distant metastasis on preoperative image
NEC ¼ neuroendocrine carcinoma; NET ¼ neuroendocrine tumor.
2 | www.md-journal.comby performing Ki-67 staining and mitotic counts according to
the World Health Organization (WHO) grading system for
NET.9 pN-stage was determined based on complete pathologi-
cal examination of a conventional distal pancreatosplenectomy.
In cases of limited pancreatectomy, pN stage was regarded as
pNx, because regional lymph nodes were not retrieved.
Statistical Analyses
FIGURE 2. Diagram for study enrollment.FIGURE 3. Incidence of pancreatectomy for NF NET-G1 of the
left side of the pancreas. NET ¼ neuroendocrine tumor; NF ¼
nonfunctioning.
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TABLE 2. Characteristics of Pancreatectomy to Treat G1 NF-
NET of the Left-Sided Pancreas
Pancreatectomy
TotalOpen MIS
EN 3 7 10
CP 1 3 4
SpDP 1 14 15
DPS 2 4 6
Total 7 28 35
CP¼ central pancreatectomy; DPS¼ distal pancreatosplenectomy;
FIGURE 4. Disease-free survival of resected NF NET-G1 of the
Medicine  Volume 94, Number 36, September 2015 Limited Pancreatectomy in Pancreatic NETwere applied to compare continuous and categorical variables,
respectively. Survival curves were estimated using the Kaplan–
Meier method to calculate cumulative disease-free survival and
disease-specific survival rates. Statistical analyses were per-
formed using SPSS 20.0 for Windows (SPSS Inc., Chicago, IL).
All P values< 0.05 were considered statistically significant.
RESULTS
Patient Characteristics
Throughout the study period, the incidence of pancrea-
tectomy for NF NET-G1 of the pancreas increased (Figure 3).
Thirty-five patients (14 males and 21 females), with a mean age
of 55.9 11.4 years, were identified with a pathologically
confirmed diagnosis of grade 1 NF neuroendocrine (islet cell)
tumor (NF NET-G1) of the left side of the pancreas. An
incidental diagnosis was noted in most patients (29 out of 35
patients, 82.9%), and abdominal discomfort was the most
common symptom. Five patients (14.3%) had NET in the neck
portion of the pancreas, 17 (48.6%) in the body, and 13 (37.1%)
in the tail, with a radiologic tumor size of 1.8 0.9 cm. Tumors
showed well demarcated margins, and there was no radiologic
evidence of local tumor invasion.
Fifteen patients (42.8%) underwent spleen-preserving dis-
tal pancreatectomy, while distal pancreatosplenectomy was
performed in 6 patients (17.1%), enucleation in 10 patients
EN¼ enuleation; MIS¼Minimally invasive surgery; NET¼
neuroendocrine tumor; SpDP¼ spleen-preserving distal pancreatec-
tomy.(28.6%), and central pancreatectomy in 4 patients (11.4%,
Table 2). Minimally invasive pancreatectomy was more fre-
quently applied to treat NF NET-G1 of the distal pancreas
TABLE 3. Chronological Change of Surgical Mode to Treat G1
NF-NET of the Left-Sided Pancreas
2005–
2009
2010–
2012
2013–
2014
P
Value
Surgical
mode 1
MIS 7 6 15 0.025
Open 4 3 0
Surgical
mode 2
LP 9 8 12 1.000
DPS 2 1 3
DPS ¼ distal pancreato-splenectomy; LP¼ limited pancreatectomy;
NET ¼ neuroendocrine tumor; NF ¼ nonfunctioning.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.(P¼ 0.025); however, there was no difference in rate of limited
pancreatectomy (P¼ 1.000, Table 3). Lymph node metastasis
was not found in 6 patients with distal pancreatectomy with
splenectomy; all others were regarded as Nx since lymph node
retrieval was not attempted during limited pancreatectomy.
Oncologic Outcomes Following Pancreatectomy
for NF NET-G1 of the Left Side of the Pancreas
All patients were found to have margin-negative resection.
During the follow-up period, a mean of 37.5 months (range,
0.6–120.0 months), disease-free survival was 36.5 months on
average (95% confidence interval [CI]: 25.9–47.1) (Figure 4).
Only 1 patient experienced local recurrence (Figure 5). Upon
retrospective reevaluation of this recurrence, we noted suspi-
cious regional lymph node metastasis before surgery (cN1) that
was underestimated in the preoperative diagnostic stage. The
patient subsequently underwent laparoscopic distal pancreatos-
plenectomy. Pathologic examination of the lesion revealed
NET-G1 lymph node metastasis. Excluding this patient, no
systemic or local recurrence was noted. There was no dis-
ease-specific mortality during the follow-up period either.
Oncologic Impact of Pathologic Characteristics
and Limited Pancreatectomy in Resected NF
NET-G1s of the Left Side of the Pancreas
Radiologic tumor size (>2.5 cm) was closely associated
with lymphovascular invasion (P¼ 0.014, Table 4). Disease-
free survival was marginally significant according to lympho-
vascular invasion (P¼ 0.093, Figure 6). There was no signifi-
cant survival differences between minimally invasive
pancreatectomy and open pancreatectomy (P¼ 0.557,
Figure 7A). In addition, no adverse oncologic impact of limited
pancreatectomy was noted in treating NF NET-G1 of the left
side of the pancreas (P¼ 0.758, Figure 7B).
DISCUSSION
left side of the pancreas. NET ¼ neuroendocrine tumor; NF ¼
nonfunctioning.Several studies suggest that regional lymph node metas-
tasis is related to poor oncologic outcomes in treating NF NETs.
Reporting on surgical outcomes for pancreatic NETs, Fisher
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rving distal pancreatectomy.
TABLE 4. Correlation Between Pathologic Characteristics and
Radiologic Tumor Size
Radiologic Tumor Size
P Value< 2.5 cm  2.5 cm
PNI No 28 5 1.000
Yes 2 0
LVI No 28 2 0.014
Yoo et al Medicine  Volume 94, Number 36, September 2015et al7 found grade 3, lymph node metastasis, and distant
metastasis to be independent prognostic factors in patients with
neuroendocrine neoplasms. Of note, they found that even small
NET-G1s (median, 1.5 cm with range, 0.4–11 cm) accom-
panied lymph node metastasis in 16.7% of the patients (28
out of 168 patients). Hashim et al15 observed that approximately
40% of their patients (50 out of 136 patients) had lymph node
metastasis, which was associated with larger tumors, tumors of
the pancreatic head, lymphovascular invasion, high Ki-67
(>20%), and poor disease-free survival. They concluded that
FIGURE 5. One case of recurrence following robotic spleen-preseregional lymphadenectomy should be included in patients
undergoing pancreatic resection for pancreatic NETs. Tsutsumi
et al16 showed that NETs of more than 1.5 cm in size are
Yes 2 3
LVI¼ lymphovascular invasion; PNI¼ perineural invasion.
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Medicine  Volume 94, Number 36, September 2015associated with a high incidence of lymph node metastasis
(25%, 10 out of 40 patients), suggesting that lymph node
dissection should be recommended in NETs larger than
1.5 cm. In resectable PNETs, Han et al17 also found that CK-
19 and KIT expression could predict clinical behavior,
advanced stage, and regional lymph node metastasis.
Although important data support the adverse oncologic
impact of lymph node metastasis and rationale for lymph node
dissection, the proportion of NF NETs in these studies is
limited,16 and no subgroup analysis has focused on NF NET-
G1.7,15,16 In addition, none have attempted to delineate recur-
rence patterns.7,15 In order to suggest the importance of lymph
node dissection in NF-NET of the pancreas, it should be clearly
shown that loco-regional recurrence is much higher in cases of
omitting lymph node dissection. However, the literature does
not support this expectation.18 Recently, Tsutsumi et al19 eval-
uated risk factors for recurrence after curative resection of well-
differentiated pancreatic NET based on the new grading classi-
fication. While their univariate analysis demonstrated lymph
FIGURE 6. Survival differences according to lymphovascular
invasion.node metastasis as a significant risk factor for tumor recurrence
(P¼ 0.0004), multivariate analysis did not (hazard ratio¼ 0.32
[95% CI: 0.01–7.98], P¼ 0.4948). Brinbaum et al20 also
FIGURE 7. Oncologic impact of minimally invasive and limited panc
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.investigated clinicopathological factors influencing survival
of NET of the pancreas and showed that lymph node metastasis
is not associated with poor disease-free survival (hazard
ratio¼ 1.11 [95% CI: 0.57–2.16], P¼ 0.74). Instead, they
concluded synchronous liver metastasis (hazard ratio¼ 3.11
[95% CI: 1.15–8.39], P¼ 0.025) and portal vein resection
(hazard ratio¼ 15.8 [95% CI: 2.60–96.40], P¼ 0.002) were
found to be independent prognostic factors for predicting tumor
recurrence. Moreover, Gratian et al21 attempted to determine
whether extent of surgery or lymph node dissection is associated
with overall survival in 1854 patients with NF NETs <2 cm.
Surprisingly, multivariate analysis demonstrated that type of
surgery and lymphadenectomy were not associated with overall
survival. Bilimoria et al22 also performed an analysis of a large
cohort of patients from the National Cancer Database
(N¼ 3851). They observed lymph node metastasis in 1384
patients (52.8%); however, lymph node status did not impact
survival in multivariate analysis (hazard ratio¼ 1.18 [95% CI:
0.96–1.45], P¼ 0.12). These all suggest that the oncologic
impact of regional lymph node metastasis is still debatable in
NETs of the pancreas and put into question the rationale of
routine regional lymph node dissection for treating NF-NET of
the pancreas.
According to our results, excluding only 1 patient whose
preoperative lymph node metastasis was underestimated on
preoperative computed tomography scan, no patients with
function-preserving limited pancreatectomy and minimally
invasive pancreatectomy experienced tumor recurrence during
the follow-up period (mean 37.5 months; range of 0.6–120.0
months). Partelli et al23 investigated clinical predictors of
lymph node involvement in NF NET of the pancreas. They
concluded that NF NET-G1 has a very low risk of lymph node
metastasis in the absence of radiological signs of node involve-
ment. Therefore, careful preoperative radiologic evaluation for
regional lymph nodemetastasis should be important in choosing
surgical option for treating NF NET-G1 of the pancreas.
Our data further discredit the oncologic role of lymph node
retrieval in NF NET-G1s of the left side of the pancreas. No
survival difference between distal pancreatosplenectomy and
limited pancreatectomy (Nx-pancreatectomy) posits the follow-
ing points: the incidence of lymph node metastasis in NF NET-
Limited Pancreatectomy in Pancreatic NETG1s of the left side of the pancreas may be very low, and the
oncologic impact of lymph node metastasis may be overesti-
mated in NF NET-G1. In our data, Nx-pancreatectomy (limited
reatectomy.
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pancreatectomy) was undertaken in 29 patients (82.9%). During
long-term follow-up, tumor recurrence was found in only 1
patient in whom lymph node metastasis was preoperatively
underestimated. Interestingly, even the patient with regional
lymph node metastasis (recurred case, Figure 5) showed a Ki-
67 index of <1%, raising doubts about the oncologic impact of
lymph node metastasis. In addition, presuming that lymph node
dissection in NF NET-G1s plays a therapeutic role, it would be
expected that oncologic outcomes for patients undergoing
regional lymphadenectomy with lymph node metastasis would
be similar to those for patients undergoing the same treatment
without lymph node metastasis. However, as the literature
suggests,21,22 poor oncologic outcomes even after regional lymph
node dissection suggest that lymph node metastasis is associated
more with aggressive tumor biology than extent of treatment.
Accordingly, the oncologic impact of lymph nodemetastasismay
not be a correctable by regional lymph node dissection.
As an important practical issue, it is impossible to know
exact histologic grades without pathological examination in
treating NF NETs of the pancreas. However, thanks to advanced
radiologic techniques, we may be able to predict not only the
status of lymph node metastasis but also tumor grade in pre-
operative settings. Kim et al24 reported that NET-G1 could be
differentiated from NET-G2 or pancreatic NEC based on pre-
operative magnetic resonance imaging images. They demon-
strated that NET-G2 and NEC exhibit specific findings, such as
ill-defined borders (P¼ 0.001) and hypo-signal intensity on
venous- and delayed-phase (P¼ 0.016), with high predictive
value for discriminating NET-G1 from G2 (P¼ 0.007).
It is well known that most NF NET-G1s <2 cm are not
eligible for surgery if they are asymptomatic and incidental.
However, according to the 2010 WHO classification of tumors,
even the smallest of tumors are given a cancer code.9 Clinical
guidelines for gastroenteropancreatic NETs in Japan indicate
surgical resection should be performed even in tumors<2 cm in
size.25 Bettini et al26 also reported that NF-NETs larger than
2 cm increased the chances of malignancy, and it was also
suggested that tumors smaller than 1 cm in size could be
malignant.27 Gratian et al21 further showed that 11% of tumors
smaller than 0.5 cm exhibit distant metastasis. Accordingly, size
is not an accurate predictor of malignancy. Nevertheless,
although several studies have failed to reveal any association
between tumor size and prognosis,28,29 tumor size is thought to
be an important clinical parameter in choosing between surgical
modalities in treating NF NET of the pancreas. We previously
reported that malignant behavior of NF NET of the pancreas is
associated with tumor size 3 cm.30 Our current observation
showed that larger tumors (>2.5 cm) are marginally associated
with tumor recurrence (P¼ 0.075) and lymphovascular inva-
sion in NF NET-G1 of the left side of the pancreas (P¼ 0.014).
Additionally, radiologic tumor size, with a cut-off value of
2.5 cm, predicted future tumor recurrence with 100% sensitivity
and a false positive rate of 11.8% (data not shown), requiring
future validation study in larger number of patients. All
together, these suggest that routine lymph node dissection is
not recommended and that lymph node dissection should be
selected upon preoperative imaging. Tailor-made surgical
approaches also need to be considered.
Based on our experiences and the following rationale, we
concluded that the oncologic impact of lymph node metastasis
in NF NET-G1 of the left side of the pancreas may be over-
Yoo et alestimated: Most NET-G1s are relatively small. Less frequent
lymph node metastasis is noted in NF NET of the left side of the
pancreas, especially in the absence of radiologic signs of node
6 | www.md-journal.cominvolvement.23 The oncologic impact of lymph node metastasis
is still controversial.22,31 Except for 1 patient with underesti-
mated lymph node metastasis, no regional recurrence was noted
even after limited pancreatectomy (current observation). Recent
studies suggest that incidental pancreatic NETs are relatively
small and nonaggressive32,33: small asymptomatic NETs
usually exhibit minimal or no growth over many years; there-
fore, a nonoperative follow-up policy may be useful in some
cases.34 Minimally invasive enucleation, central pancreatect-
omy, and left-sided pancreatectomy are feasible and safe.35–37
Notwithstanding, large volume-based studies are needed to
validate the current suggestion and clinical observations. In
addition, considering the low proliferative power of NF NET-
G1 (Ki67 index <1%), more long-term follow-up study should
conducted to reach a concrete conclusion.
In conclusion, our results further put into doubt the onco-
logic impact of lymph node metastasis in NF NET-G1 of the left
side of the pancreas. Therefore, routine conventional distal
pancreatectomy with splenectomy for retrieving regional lymph
nodes may be too extensive in NF NET-G1. Minimally invasive
and function-preserving pancreatectomy is recommended in
well-selected NF NET-G1 as long as there are relevant pre-
dicting models to predict tumor grade before surgery. Future
studies to help realize tailored surgical approaches for use in
treating NF NET of the left side of the pancreas are warranted.
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